Characteristics and clinical outcome of BRCA germline mutation carriers with advanced breast cancer treated with PARP (poly ADP-ribose polymerase) inhibitors: A single institution experience.

被引：0
|
作者：
Mustafayev, Fatma Nihan Akkoc [1 ]
Munsell, Mark [1 ]
Gutierrez-Barrera, Angelica M. [1 ]
Yam, Clinton [1 ]
Layman, Rachel M. [1 ]
Arun, Banu [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10587
引用
收藏
页数：1
相关论文
共 50 条
  • [31] New Roles of Poly(ADP-Ribose) Polymerase Inhibitors in the Treatment of Breast Cancer
    Harvey-Jones, Elizabeth
    Villaro, Gemma Vinas
    Tutt, Andrew
    CANCER JOURNAL, 2021, 27 (06) : 441 - 456
  • [32] The emerging potential of poly(ADP-ribose) polymerase inhibitors in the treatment of breast cancer
    Drew, Yvette
    Plummer, Ruth
    CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2010, 22 (01) : 67 - 71
  • [33] Triple-negative Breast Cancer and Poly(ADP-ribose) Polymerase Inhibitors
    Park, Youngjin
    Moriyama, Ayako
    Kitahara, Tomoaki
    Yoshida, Yutaka
    Urita, Tasuku
    Kato, Ryoji
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2012, 12 (06) : 672 - 677
  • [34] Poly ADP ribose polymerase (PARP) for the treatment of BRCA-mutated advanced ovarian cancer
    Yunokawa, Mayu
    ANNALS OF ONCOLOGY, 2019, 30 : 47 - 47
  • [35] Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer
    Zheng, Feiyue
    Zhang, Yi
    Chen, Shuang
    Weng, Xiang
    Rao, Yuefeng
    Fang, Hongmei
    BIOMEDICINE & PHARMACOTHERAPY, 2020, 123
  • [36] Poly(ADP-Ribose) Polymerase in Cervical Cancer Pathogenesis Mechanism and Potential Role for PARP Inhibitors
    Kotsopoulos, Ioannis C.
    Kucukmetin, Ali
    Mukhopadhyay, Asima
    Lunec, John
    Curtin, Nicola J.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 (04) : 763 - 769
  • [37] Development of new poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer: Quo Vadis?
    Boussios, Stergios
    Moschetta, Michele
    Karihtala, Peeter
    Samartzis, Eleftherios P.
    Sheriff, Matin
    Pappas-Gogos, George
    Ozturk, Mehmet Akif
    Uccello, Mario
    Karathanasi, Afroditi
    Tringos, Michail
    Rassy, Elie
    Pavlidis, Nicholas
    ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (24)
  • [38] Poly(ADP-Ribose) Polymerase (PARP) Inhibitors for Cancer Therapy: Advances, Challenges, and Future Directions
    Bondar, Denys
    Karpichev, Yevgen
    BIOMOLECULES, 2024, 14 (10)
  • [39] Clinical Trials of Poly(ADP-Ribose) Polymerase Inhibitors for Cancer Therapy: A Review
    Buege, Michael
    Mahajan, Pramod B.
    REVIEWS ON RECENT CLINICAL TRIALS, 2015, 10 (04) : 326 - 339
  • [40] Poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors in cancer chemotherapy
    Cepeda, Victoria
    Fuertes, Miguel A.
    Castilla, Josefina
    Alonso, Carlos
    Quevedo, Celia
    Soto, Manual
    Perez, Jose M.
    RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2006, 1 (01) : 39 - 53
12345